

***Fiscal Year 2024 Department of Defense Tick-Borne Disease Research Program (TBDRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Idea Development Award (IDA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT942524TBDRPIDA</a></p>	<p><b>IDA:</b></p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent).</p> <p><b>IDA – Career Development Option:</b></p> <ul style="list-style-type: none"> <li>• <b>Principal Investigator (PI):</b> Investigator within 10 years of completing their terminal degree at the time of application submission deadline and working to become an independent investigator in tick-borne disease (TBD) research.</li> <li>• <b>Mentor:</b> Independent investigator at or above the level of Associate Professor (or equivalent); must be an experienced TBD researcher as demonstrated by a recent history of funding and publications in TBD research, specifically in the field of the proposed studies.</li> <li>• <i>Mentorship is required. The PI and Mentor may be at different organizations.</i></li> </ul>	<ul style="list-style-type: none"> <li>• <b>IDA-specific Pathogenesis, Treatment, and Diagnosis Focus Areas only.</b></li> <li>• Supports research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other TBDs and conditions and improving patient care and/or quality of life.</li> <li>• Research should be conceptually innovative, introduce a new concept or question, challenge existing paradigms, approach issues from a new perspective or exhibit other uniquely creative qualities.</li> <li>• Applications must describe the <b>short- and long-term impact</b> of the proposed research, as well as the <b>public health burden</b> of the diseases being addressed.</li> <li>• <b>The Career Development Option</b> is intended to fund <b>early-career investigators</b> to conduct impactful research under the <b>mentorship</b> of an experienced TBD researcher. Applications submitted under this option will be reviewed via separate, career development-specific evaluation criteria by a separate, dedicated peer review panel.</li> <li>• <b>Inclusion of preliminary data relevant to the proposed studies is not prohibited, but in its absence, strong rationale for achieving interpretable results must be provided.</b></li> <li>• <b>Clinical trials are not allowed; human studies/clinical research are permitted.</b></li> <li>• <b>Pre-application submission is required; application submission is by invitation only.</b></li> </ul>	<p><b>IDA:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$525,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul> <p><b>IDA – Career Development Option:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$350,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 26, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Therapeutic/Diagnostic Research Award (TDRA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">HT942524TBDRPTDRA</a></p>	<p><b>TDRA:</b></p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li><b><i>TDRA-specific Treatment and Diagnosis Focus Areas only.</i></b></li> <li>Supports hypothesis-driven therapeutic and diagnostic development research with demonstrated feasibility to reduce the burden of Lyme disease and/or other TBDs and conditions and improving patient care and/or quality of life. <ul style="list-style-type: none"> <li>Treatment-focused applications should be therapeutic evaluation studies designed to advance drugs or treatments that are still in the preclinical stages of development.</li> <li>Diagnosis-focused applications should be diagnostic evaluation studies to advance approaches that will be readily integrated into clinical settings.</li> </ul> </li> <li>Research should have translational potential, with proposed studies expected to be empirical in nature and product-driven.</li> <li>Applicants with limited TBD experience are strongly encouraged to collaborate with experienced TBD investigators.</li> <li>Applicants with substantial TBD experience are strongly encouraged to partner with experts in therapeutic and diagnostic assay development and transition, particularly those from the commercial sector.</li> <li><b>Preliminary data are required.</b></li> <li><b>Clinical trials are not allowed; human studies/clinical research are permitted.</b></li> <li><b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<p><b>TDRA:</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$830,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 26, 2024 5:00 p.m. ET</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. ET</p>